SLC5A2 and type 2 diabetes mellitus: In individuals with T2DM, clinical studies using the most advanced SGLT2 inhibitors, dapagliflozin and canagliflozin, have shown therapeutic improvements in terms of glycemic control, plasma glucose level, and reduced weight gain.